Triple therapy aims to shrink head and neck tumors before surgery
NCT ID NCT07552558
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of an experimental drug (ficerafusp alfa), an immunotherapy (pembrolizumab), and targeted radiation before surgery for people with advanced head and neck cancer that is HPV-negative. About 45 participants will receive these treatments over several weeks, then undergo standard surgery and follow-up care. The goal is to see if this approach can completely eliminate the tumor in the removed tissue and to find the safest radiation dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ficerafusp alfa (BCA101) plus pembrolizumab (Keytruda) plus stereotactic body radiotherapy (SBRT)
What this could lead to
If successful, this combination could become a new pre-surgery treatment to shrink tumors more effectively in advanced head and neck cancer.
What could go wrong
This is an early phase 1/2 trial with only 45 participants, so results are preliminary. The added drugs and radiation may cause significant side effects, and not all patients may benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact